Table II.
Anti-proliferative activity of Matrine and its derivatives.
| IC50 (µM) | |||||
|---|---|---|---|---|---|
| Compounds | BT-20 | A549 | MCF-7 | U20S | CLogP |
| Matrine | 301.60±23.45 | 425.30±24.67 | 216.50±16.89 | 152.00±11.36 | 1.36 |
| YF3-3 | 495.50±34.38 | 353.90±17.67 | 204.50±17.82 | 189.10±12.86 | 3.25 |
| YF3-5 | 16.67±1.34 | 15.49±1.04 | 15.88±1.27 | 16.39±1.31 | 5.36 |
| YF3-7 | 136.60±10.45 | 117.90±6.89 | 126.10±8.96 | 85.09±5.223 | 3.76 |
| YF3-9 | 147.00±15.57 | 183.40±9.32 | 112.30±8.23 | 85.20±4.36 | 3.68 |
| RW-23 | 260.50±10.21 | 247.60±10.78 | 231.60±15.37 | 189.00±18.32 | 3.95 |
The cytotoxic effects of the compounds on different cancer cells were assessed by MTT assay. Results are presented as the mean ± standard deviation of three independent experiments with triplicates in each experiment.